Transporting the AstraZeneca COVID-19 Vaccine from PCN designated sites to end user locations, patients’ homes and within the PCN Grouping

David Erskine, Director, London Medicines Information Services, Specialist Pharmacy ServicePublished Last updated See all updates

SOP for transporting the AstraZeneca COVID-19 Vaccine from PCN designated sites to end user locations, patients’ homes and within the PCN Grouping.

A standard operating procedure is attached to this page. This is based on the content of the NHSE/I letter ‘COVID-19 Vaccine Oxford AstraZeneca – movement of vaccine‘ of 7th January 2021, the NHSE/I ‘Position Statement around use of the Covid-19 Vaccine AstraZeneca (AZ) to vaccinate housebound patients‘ of 11th January 2021 and the Position Statement for the vaccination of Care Home residents using COVID-19 vaccine AstraZeneca (AZ). of 1st February 2021.

You should also familiarise yourself with our background guide Facilitating pharmaceutical support to PCN designated sites for COVID-19 vaccinations before using this SOP.

 

 

What to do if you still have questions

If you still have questions you can get in touch with us. However, please first read our service remit; and if you still think we can help, use the email address below.

We're supporting healthcare professionals in England with pharmaceutical aspects of the COVID-19 vaccination programme; read our service remit to find out more.
If you're a healthcare professional in England, get in touch with us if you still have questions

Change history

  1. Updated to reflect Position Statement on vaccination of Care Home residents dated 01/02/2021 and the Mutual Aid policy

  2. Rationale for advice on transfer of used vials clarified

  3. Updated to clarify storage of vaccine at GP practice

  4. Updated to support transfer of used vaccine vial between patients' homes and clarification that the vaccine received at GP practice must be used immediately and not stored

  5. Published